Reduction in the risk of back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis
Jean‐Yves Reginster(King Saud University), John H. Krege(Eli Lilly (United States)), Robin K. Dore(University of California, Los Angeles), Emmett V. Glass(Eli Lilly (United States)), P. Chen(Eli Lilly (United States)), Michael C. Nevitt(University of California, San Francisco), DP Kiel, José Zanchetta(Universidad del Salvador)
Open Repository and Bibliography (University of Liège)
June 1, 2005
Cited by 0
Related Papers
Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2012|2.9k
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
|Osteoporosis International|2018|1.8k
Generation and reproductive phenotypes of mice lacking estrogen receptor β
|Proceedings of the National Academy of Sciences|1998|1.7k